In the event, death from acute tedium proved a graver risk.
During a median follow-up period of 8.2 months (25% and 75% centiles, 3.3 and 18.9 months), 47 patients had a cardiac event (death or urgent heart transplantation).
Current clinical trials continue to study similar endpoints since late 1960s mainly time to an event (death, first relapse, metastasis, disease recurrence, or death from a particular cause).
Hazards Ratios (HR) with 95% CIs show the risk of experiencing the event (death from any cause) during the follow-up period.
Lack of ACS was determined by negative diagnostic testing or absence of a cardiac event (death, myocardial infarction, or revascularization) during the 30-day follow-up period.
OBJECTIVE To estimate the cost per ischaemic event (death, nonfatal myocardial infarction, subsequent revascularisation procedure) avoided at 6 months in high risk patients undergoing coronary revascularisation treated with abciximab during routine medical care.
This study investigated whether lipofuscin or fibrosis had predictive utility in indicating function or adverse event (death, transplant, assist device placement) at 1 year postbiopsy in adolescents and young adults.
His goal was to find a mix of clinical indicators that retrospectively "predicted" which patients ultimately experienced a critical event (death, intensive care admission, emergent surgery, or catheterization) or required hospital admission.
A first event death at Day 10, one-day post-operatively (patient 0704) was recorded.
A total of 66 patients had an OS event (death).
Response options were: inconvenience, temporary disability, permanent disability, an acute life-threatening event, death, or none.
